2022 ICTS Symposium Agenda and Speakers


Friday May 13, 2022, 9am – 12:30pm, Central Time
Attendance will be offered in-person at the Eric P. Newman Center on the Medical School Campus or via Zoom Webinar.

8:30amIn-person attendee check-in.
9:00–9:25amWelcome by ICTS Director William Powderly, MD

School of Medicine Remarks by Dean David Perlmutter, MD

“Celebrating 15 Years of Translational Excellence”

Director William Powderly will highlight ICTS achievements and discuss future initiatives as the ICTS embarks upon its fourth cycle of consecutive funding from the National Center for Advancing Translational Sciences. Winners of the poster competition will be announced.
9:25–10:25amKeynote Panel with
L. Ebony Boulware, MD; Mario Castro, MD, MPH; and Rebecca Jackson, MD
Moderated by William Powderly, MD

“The Time is Now: Advancing Health Equity through the CTSA Program”

The CTSA program is uniquely positioned to strengthen multidisciplinary research through collaboration and shared infrastructure. Principal Investigators from three CTSA hubs will share insights and strategies to increase health equity and diversity that have been implemented at their institutions. How the consortium can be leveraged to achieve maximum impact will be discussed.

“Generating an Equity Mindset in Translational Research”
L. Ebony Boulware, MD, MPH, CTSA PI Duke University

“Increasing Workforce Diversity as a Shared CTSA Investment”
Mario Castro, MD, MPH, CTSA PI University of Kansas Medical Center

“Bridging Digital Divides: Approaches to Improve Data Equity and Reduce Data Biases”
Rebecca D. Jackson, MD, CTSA PI The Ohio State University
10:25–11:00amPresentation by Doug Lindsay, Rare disease advocate and personal medical consultant

“Subject or Subject Matter Expert? Just Ask Them.”

When you ask the question “When should we involve patients in the research process?” the answer is this: at every stage. Doug Lindsay will discuss how to co-design both your studies and dissemination strategies with patients to boost enrollment and impact.
11:15–12:30pmClinical Trials Panel with
Thomas Kannampallil, PhD; Doug Lindsay; Jessica Mozersky, PhD; Yi Zhang, RN, JD
Moderated by Christina Gurnett, MD, PhD, ICTS Associate Director

“Increasing Diverse Representation in Clinical Trials”

Increased representation of diverse populations in research is crucial to health equity. This panel will examine challenges and solutions in the context of community engagement, informatics, recruitment, workforce diversity, and evaluation.
12:30pmBoxed lunches available.


L. Ebony Boulware, MD, MPH

L. Ebony Boulware, MD, MPH

Nanaline H. Duke Distinguished Professor of Medicine; Chief, Division of General Internal Medicine; Director, Clinical and Translational Science Institute; Duke University School of Medicine

Boulware is a general internist, physician-scientist, clinical epidemiologist, and health services researcher devoted to improving health and health equity for marginalized individuals and communities. She directs the Duke Clinical and Translational Science Institute, and she serves as vice dean for Translational Science and Associate Vice Chancellor for Translational Research. Throughout her work, Boulware has sought to improve transparency and trustworthiness in science and medicine. She frequently engages community members, patients, and their family members to enhance the relevance and sustainability of her research.
Mario Castro, MD, MPH

Mario Castro, MD, MPH

L. E. Phillips and Lenora Carr Phillips Professor; Chief, Pulmonary, Critical Care and Sleep Medicine; Vice Chair for Clinical and Translational Research; Director, Frontiers Clinical and Translational Science Institute; University of Kansas Medical Center

Castro has been a leader of the CDC Controlling Asthma in American Cities, ALA Clinical Research Centers, and NHLBI Asthma Clinical Research Network, Severe Asthma Research Program, AsthmaNet and PrecISE research networks. His translational research focuses on the pathogenesis and treatment of asthma, especially in severe disease. Castro’s recent COVID-19 research includes: lead investigator for NIH/NIAID-funded COVID-19 Prevention Trials Network, ACTIV-2 trial, and the PCORNET HERO HCQ trial. He is widely recognized as an expert clinician, an excellent mentor, and skilled educator with a commitment to the development of young investigators’ careers.
Christina Gurnett, MD, PhD

Christina Gurnett, MD, PhD

A. Ernest and Jane G. Stein Professor of Developmental Neurology; Professor of Neurology, Pediatrics; Associate Director, Institute of Clinical and Translational Sciences; Director, Division of Pediatric and Developmental Neurology; Neurologist-in-Chief, St Louis Children’s Hospital; Washington University School of Medicine in St. Louis

Gurnett is a physician-scientist who is the director of the Clinical and Translational Core of the Washington University Intellectual and Developmental Disabilities Research Center. She completed her MD and PhD degrees at the University of Iowa and came to Washington University School of Medicine in 2000 for neurology residency and a clinical neurophysiology fellowship. Since 2014, she has co-directed the precision medicine pathway for graduate students. She has an active research laboratory whose goals include gene discovery for musculoskeletal disorders and the development of high throughput methods to improve variant interpretation. She is also the co-PI for two RADx-UP Return to School testing projects for COVID-19.
Rebecca D. Jackson, MD

Rebecca D. Jackson, MD

Professor, Endocrinology, Diabetes and Metabolism; Max Morehouse Chair of Cancer Research; Director, Center for Clinical and Translational Science; Associate Dean, Clinical and Translational Research; The Ohio State University

Jackson is the founding director of the Center for Clinical and Translational Science at The Ohio State University. Her research is focused on defining clinical factors, biomarkers and genetic associations for diseases that disproportionately affect women. She recently convened a team across six Ohio universities, 19 communities and the state that was funded to participate in the NIDA HEALing Communities Study. Her laboratory has been continuously funded for three decades and she has authored/co-authored more than 270 peer-reviewed manuscripts. She is also a nationally-recognized leader in translational science workforce development.
Thomas Kannampallil, PhD

Thomas Kannampallil, PhD

Assistant Professor of Anesthesiology, Medicine and Computer Science; Associate Chief Research Information Officer; Washington University School of Medicine in St. Louis

Kannampallil is an assistant professor in the Washington University School of Medicine’s Department of Anesthesiology and the Institute for Informatics. His research interests lie at the intersection of computer science, cognitive science, and clinical informatics. Specifically, he focuses on developing and evaluating intelligent computational tools for improving clinical decision making and patient safety. Within this context, he has extensive experience in developing and implementing electronic health records.
Doug Lindsay, BS

Doug Lindsay, BS

Personal Medical Consultant

Profiled in CNN’s top health story of 2019, Doug Lindsay got sick at 21, spent 11 years homebound and bedbound suffering from a debilitating unknown illness until he figured out what was wrong, developed new treatments to keep it at bay, and partnered with doctors and scientists to develop the innovative surgery used to treat his rare autonomic-adrenal condition. Lindsay is a nationally-recognized keynote speaker. He’s been featured in PEOPLE Magazine and the BBC, and is co-chair of PCORI’s Rare Disease Advisory Panel and co-chair of Washington University’s Community Advisory Board for the Institute of Clinical and Translational Sciences and the Institute for Public Health.
Jessica Mozersky, PhD

Jessica Mozersky, PhD

Assistant Professor of Medicine; Director of Consultation, Bioethics Research Center Washington University School of Medicine in St. Louis

Mozersky is trained in anthropology and holds a Master degree in bioethics. Her research explores the ethical, legal, and social implications of new genetic and biomedical technologies. Mozersky is PI or co-investigator for numerous NIH funded projects on topics including return of biomarker results that indicate of risk of Alzheimer Disease to healthy older adults, recruitment and retention of underserved populations, pediatric and adult cancer genetic testing, informed consent, and qualitative data sharing.
William Powderly, MD

William Powderly, MD

J. William Campbell Professor of Medicine; Associate Dean for Clinical and Translational Sciences; Director, Institute of Clinical and Translational Sciences; Larry J. Shapiro Director, Institute for Public Health; Co-Director of the Division of Infectious Diseases; Washington University School of Medicine in St. Louis

Powderly is currently director of the Washington University Institute for Public Health, director of the Institute of Clinical and Translational Sciences, and co-director of the Division of Infectious Diseases. He has been actively involved in HIV-related clinical research for thirty years. He has been a member of numerous advisory groups on HIV and infectious diseases for the NIH, the CDC, the Canadian Institute for Health Research, and the European Medicines Agency. His major recent focus is translating scientific advances to a wider population to improve public health.
Yi Zhang, RN, JD

Yi Zhang, RN, JD

Assistant Dean for Clinical Research; Administrative Director, Center for Clinical Studies; Operations Officer, Clinical and Translational Research Unit; Director, Clinical Research in Oncology; Washington University School of Medicine in St. Louis

Zhang has expertise in clinical research, and operational, regulatory, legal, ethical and practical issues faced by clinical research investigators and staff. She has served the ICTS in different capacities across several domains and cores. Currently, she serves as the operations officer for the Clinical and Translational Research Unit and the co-director of the Regulatory Knowledge and Support Center, as well as playing a major role in the ICTS’ Network Capacity component.